Characterization of ribosomal binding and antibacterial activities using two orthogonal high-throughput screens

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4717-4726

  King, Ada ^a   Watkins, Derrick ^a   Kumar, Sunil ^b   Ranjan, Nihar ^b   Gong, Changjun ^b   Whitlock, Jarred ^a   Arya, Dev P ^a,b  

^a NUBAD LLC   (United States)

^b CLEMSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; FLUORESCEIN; NEOMYCIN; RIBOSOME RNA;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BINDING ASSAY; BROTH DILUTION; CONTROLLED STUDY; DRUG DETERMINATION; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR BIOLOGY; MOLECULAR LIBRARY; NONHUMAN; PRIORITY JOURNAL; RIBOSOME BINDING; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; ENTEROBACTER CLOACAE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; NEOMYCIN; PSEUDOMONAS AERUGINOSA; RIBOSOMES; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84884255205     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00671-13     Document Type: Article

References (41)

1. Willis B, Arya DP. 2006. An expanding view of aminoglycoside-nucleic acid recognition. Adv. Carbohydr. Chem. Biochem. 60:251-302.
2. Livermore DM. 2012. Current epidemiology and growing resistance of gram-negative pathogens. Korean J. Intern. Med. 27:128-142.
3. Livermore DM. 2003. Bacterial resistance: origins, epidemiology, and impact. Clin. Infect. Dis. 36:S11-S23.
4. Walsh C. 2000. Molecular mechanisms that confer antibacterial drug resistance. Nature 406:775-781.
5. Scheunemann AE, Graham WD, Vendeix FA, Agris PF. 2010. Binding of aminoglycoside antibiotics to helix 69 of 23S rRNA. Nucleic Acids Res. 38:3094-3105.
6. Dibrov SM, Parsons J, Hermann T. 2010. A model for the study of ligand binding to the rRNA helix h44. Nucleic Acids Res. 38:4458-4465.
7. Yonath A. 2005. Antibiotics targeting ribosomes: resistance, selectivity, synergism, and cellular regulation. Annu. Rev. Biochem. 74:649-679.
8. Vaheri A, Pagano JS. 1965. Infectious poliovirus RNA: a sensitive method of assay. Virology 27:434-436.
9. Vicens Q, Westhof E. 2001. Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A-site. Structure 9:647-658.
10. Vicens Q, Westhof E. 2002. Crystal structure of a complex between the aminoglycoside tobramycin and an oligonucleotide containing the ribosomal decoding A-site. Chem. Biol. 9:747-755.
11. Barbieri CM, Kaul M, Pilch DS. 2007. Use of 2-aminopurine as a fluorescent tool for characterizing antibiotic recognition of the bacterial rRNA A-site. Tetrahedron 63:3567-6574.
12. Yoshizawa S, Fourmy D, Puglisi JD. 1998. Structural origins of gentamicin antibiotic action. EMBO J. 17:6437-6448.
13. Barbieri CM, Kaul M, Bozza-Hingos M, Zhao F, Tor Y, Hermann T, Pilch DS. 2007. Defining the molecular forces that determine the impact of neomycin on bacterial protein synthesis: importance of the 2=-amino functionality. Antimicrob. Agents Chemother. 51:1760-1769.
14. Bera S, Dhondikubeer R, Findlay B, Zhanel GG, Schweizer F. 2012. Synthesis and antibacterial activities of amphiphilic neomycin B-based bilipid conjugates and fluorinated neomycin B-based lipids. Molecules 17:9129-9141.
15. Dhondikubeer R, Bera S, Zhanel GG, Schweizer F. 2012. Antibacterial activity of amphiphilic tobramycin. J. Antibiot. (Tokyo) 65:495-498.
16. Findlay B, Zhanel GG, Schweizer F. 2012. Neomycin-phenolic conjugates: polycationic amphiphiles with broad-spectrum antibacterial activity, low hemolytic activity and weak serum protein binding. Bioorg. Med. Chem. Lett. 22:1499-1503.
17. Bera S, Zhanel GG, Schweizer F. 2011. Synthesis and antibacterial activity of amphiphilic lysine-ligated neomycin B conjugates. Carbohydr. Res. 346:560-568.
18. Bera S, Zhanel GG, Schweizer F. 2010. Antibacterial activity of guanidinylated neomycin B-and kanamycin A-derived amphiphilic lipid conjugates. J. Antimicrob. Chemother. 65:1224-1227.
19. Zhang J, Keller K, Takemoto JY, Bensaci M, Litke A, Czyryca PG, Chang CW. 2009. Synthesis and combinational antibacterial study of 5-modified neomycin. J. Antibiot. (Tokyo) 62:539-544.
20. Kling D, Chow C, Mobashery S. 2007. Binding of antibiotics to the aminoacyl-tRNA site of bacterial ribosome, p 225-233. In Arya DP (ed), Aminoglycoside antibiotics: from chemical biology to drug discovery. John Wiley & Sons, Inc., Hoboken, NJ.
21. Russell RJ, Murray JB, Lentzen G, Haddad J, Mobashery S. 2003. The complex of a designer antibiotic with a model aminoacyl site of the 30S ribosomal subunit revealed by X-ray crystallography. J. Am. Chem. Soc. 125:3410-3411.
22. Haddad J, Kotra LP, Llano-Sotelo B, Kim C, Azucena EF, Jr, Liu M, Vakulenko SB, Chow CS, Mobashery S. 2002. Design of novel antibiotics that bind to the ribosomal acyltransfer site. J. Am. Chem. Soc. 124:3229-3237.
23. Llano-Sotelo B, Azucena EF, Kotra LP, Mobashery S, Chow CS. 2002. Aminoglycosides modified by resistance enzymes display diminished binding to the bacterial ribosomal aminoacyl-tRNA site. Chem. Biol. 9:455-463.
24. Sucheck SJ, Wong AL, Koeller KM, Boehr DD, Draker K, Sears P, Wright GD, Wong C. 2000. Design of bifunctional antibiotics that target bacterial rRNA and inhibit resistance-causing enzymes. J. Am. Chem. Soc. 122:5230-5231.
25. Greenberg WA, Priestley ES, Sears PS, Alper PB, Rosenbohm C, Hendrix M, Hung S, Wong C-H. 1999. Design and synthesis of new aminoglycoside antibiotics containing neamine as an optimal core structure: correlation of antibiotic activity with in vitro inhibition of translation. J. Am. Chem. Soc. 121:6527-6541.
26. Alper PB, Hendrix M, Sears P, Wong C-H. 1998. Probing the specificity of aminoglycoside-rRNA interactions with designed synthetic analogs. J. Am. Chem. Soc. 120:1965-1978.
27. Wong CH, Hendrix M, Manning DD, Rosenbohm C, Greenberg WA. 1998. A library approach to the discovery of small molecules that recognize RNA: use of a 1,3-hydroxyamine motif as core. J. Am. Chem. Soc. 120:8319-8327.
28. Wong CH, Hendrix M, Priestley ES, Greenberg WA. 1998. Specificity of aminoglycoside antibiotics for the A-site of the decoding region of rRNA. Chem. Biol. 5:397-406.
29. Hendrix M, Priestley ES, Joyce GF, Wong CH. 1997. Direct observation of aminoglycoside-RNA interactions by surface plasmon resonance. J. Am. Chem. Soc. 119:3641-3648.
30. Watkins D, Norris FA, Kumar S, Arya DP. 2013. A fluorescence-based screen for ribosome binding antibiotics. Anal. Biochem. 434:300-307.
31. De La Fuente R, Sonawane ND, Arumainayagam D, Verkman AS. 2006. Small molecules with antimicrobial activity against Escherichia coli and Pseudomonas aeruginosa identified by high-throughput screening. Br. J. Pharmacol. 149:551-559.
32. Liu KC, Fang JM, Jan JT, Cheng TJ, Wang SY, Yang ST, Cheng YS, Wong CH. 2012. Enhanced anti-influenza agents conjugated with antiinflammatory activity. J. Med. Chem. 55:8493-8501.
33. Su CY, Cheng TJ, Lin MI, Wang SY, Huang WI, Lin-Chu SY, Chen YH, Wu CY, Lai MM, Cheng WC, Wu YT, Tsai MD, Cheng YS, Wong CH. 2010. High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity. Proc. Natl. Acad. Sci. U. S. A. 107:19151-19156.
34. Cochrane A, Murley LL, Gao M, Wong R, Clayton K, Brufatto N, Canadien V, Mamelak D, Chen T, Richards D, Zeghouf M, Greenblatt J, Burks C, Frappier L. 2009. Stable complex formation between HIV Rev and the nucleosome assembly protein, NAP1, affects Rev function. Virology 388:103-111.
35. Kumar S, Kellish P, Robinson WE, Wang D, Appella DH, Arya DP. 2012. Click dimers to target HIV TAR RNA conformation. Biochemistry 51:2331-2347.
36. Kumar S, Arya DP. 2011. Recognition of HIV TAR RNA by triazole linked neomycin dimers. Bioorg. Med. Chem. Lett. 21:4788-4792.
37. Kumar S, Xue L, Arya DP. 2011. Neomycin-neomycin dimer: an allcarbohydrate scaffold with high affinity for AT-richDNAduplexes. J. Am. Chem. Soc. 133:7361-7375.
38. National Committee for Clinical Laboratory Standards. 1997. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals; approved standard, 2nd ed. NCCLS document M31-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
39. Cudic M, Lockatell C, Johnson D, Otvos L. 2003. In vitro and in vivo activity of an antibacterial peptide analog against uropathogens. Peptides 24:807-820.
40. Helander IM, Mattila-Sandholm T. 2000. Fluorometric assessment of gram-negative bacterial permeabilization. J. Appl. Microbiol. 88:213-219.
41. Toth M, Chow JW, Mobashery S, Vakulenko SB. 2009. Source of phosphate in the enzymic reaction as a point of distinction among aminoglycoside 2'-phosphotransferases. J. Biol. Chem. 284:6690-6696.